Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 1996

View Archived Issues

Ciba-Geigy reports on further NK1 antagonists

New analgesic drugs presented at 8th World Congress on Pain

U.S. approval for anesthetic/analgesic agent

Dusa reports phase I/II results on ALA PDT for acne

Human Genome Sciences claims new growth factor

Pivotal European trial to begin on wound-healing product from Life Medical Sciences

Penam sulfones with beta-lactamase-inhibitory activity

Metallo-beta-lactamase inhibitors from SKB

Procter & Gamble focuses on multifunctional antibacterial agents

MC-02331, a new cephalosporin with excellent activity against Gram-positive bacteria

Fujisawa antibiotic awaiting MHW approval

Yamanouchi awaits marketing approval for Farom

New family of marine natural products discovered

Daiichi discloses quinolone antibacterial agents

Cubist evaluating new class of antibacterial agents

Xoma poised to enter pivotal trials with Neuprex

Azole antifungals reported by Takeda

Genes associated with latent CMV infection discovered

Anti-HIV agents from Department of Health & Human Services

Anti-HIV agents from Nippon Paper

EU approval for Roche AIDS drug

Merck & Co. cleared to market protease inhibitor in EU

Ingenol derivatives as anti-HIV agents

IND filed for MiKasome

Novel strategy for AIDS reported by UCSF researchers

HIV inhibited by chemokine antagonist

Searle continues to investigate COX-2 inhibitors for inflammation

Celecoxib development status in Japan

Federal research grant for novel genetic approach to arthritis

Important milestone for Connective Therapeutics' ConXn

Cel-Sci forms collaboration for development of herpesvirus vaccine

SangStat's ciclosporin bioequivalent to Sandoz drug

Cytel-Baxter xenotransplantation collaboration

First recombinant DTaP vaccine submitted for FDA approval

Evidence indicates wider application of VasoCare therapy

BioTransplant's transplant technologies covered by four new patents

Successful reversal of acute kidney graft rejection with Thymoglobulin

New combination meningitis/hepatitis vaccine approved

Fujisawa pursues new indications for tacrolimus

FK-317, a new antitumor antibiotic from Fujisawa

Antitumor antibiotics from the Kitasato Institute

Nippon Kayaku evaluates novel doxorubicin preparation

Pierre Fabre discloses topoisomerase II inhibitors

Orphan drug status granted for camptothecin derivative

Schering AG's tubulin polymerization inhibitors for cancer

Daiichi claims new taxol derivatives

Endorecherche claims EM-800 for estrogen-dependent disorders

Antineoplastic aromatase inhibitor from Yamanouchi shows potential for hormone-related illnesses

Chemokine polypeptide from Human Genome Sciences has multiple potential uses

New company focuses on small molecules that mimic binding regions of Ig proteins

Patent coverage for The Immune Response Corporation's colon cancer vaccine

Ovarian cancer vaccine enters phase II/III trials

Farnesyltransferase inhibitors discovered by RPR

Merck describes natural inhibitors of Ras farnesylation

ProScript licenses rights to inhibitors of Ras processing

MMP inhibitors from Otsuka

DuPont Merck describes bisnaphthalimide anticancer drugs

Japanese researchers report new antimetastatic agents

Kanebo reports antitumor agent with a novel mechanism of action

SuperGen acquires rights to Warner-Lambert anticancer drug

Clinical trial program for anticancer HER-2/neu inhibitor

First photodynamic therapy approved in the U.S.

New strategy for reducing doxorubicin toxicity

Gene therapy reduces the side effects of chemotherapy

New use for Uriach's rupatadine

Second Hedgehog-based research collaboration for Ontogeny

New hypocholesterolemic agent from Schering-Plough

Generic cholestyramine cleared by FDA

Pravastatin continues to demonstrate clinical utility in various patient groups

Appetite-suppressing effects of urocortin

ProScript and Roche to develop compounds for cachexia

Future metabolic agents in the Yamanouchi pipeline

Cocaine vaccine proven effective in animal model

Japanese scientists discover potential agent for siderosis

American Biogenetic Sciences and Gull form joint venture

Gensia to file NDA amendment for GenESA System

Diatide begins phase II trial of imaging agent for locating infections

Second approval for CEA-Scan

Sonus and Abbott sign second licensing agreement for EchoGen

Hypnotic agent in the Fujisawa pipeline

Suntory reports agents for CNS and cerebrovascular disorders

New dopamine receptor ligands reported by Neurogen

Dopamine D3 ligands from Pharmacia & Upjohn

Potential antipsychotic agents disclosed by Pharmacia & Upjohn

First launch for olanzapine

ArQule-Roche Bioscience collaborative agreement

Dyax grants additional licenses for phage display technology

Important milestone reached in Pharmacopeia-Schering-Plough collaboration

Inex and Schering-Plough extend collaboration on gene delivery systems

First U.S. launch of product using Scherer's Zydis technology

Alkermes' RMP-7 advances through clinical trials

Patent allowance for SuperGen technology for cancer drug formulation

Patent coverage for new gene expression system

Geron licenses technologies for use in the treatment of age-related diseases

Palatin receives grants for the development of peptide-based therapeutics and diagnostics

ICN expands its presence in Russia

Cambridge Biotech set to implement reorganization plan

Victoria Enterprises-BioQuest merger

Alliance to acquire MDV Technologies

Mimetix Company Profile

Hemagen Diagnostics Company Profile

FDA approval for Taro generic drug

Copaxone approvable for MS

New muscarinic antagonists from Schering-Plough

Calpain inhibitors reported by Warner-Lambert

Novel free radical-scavenging and neuroprotective substance isolated by Japanese researchers

Novel treatment for chronic fatigue syndrome available in Canada

Yamanouchi's CNS products in the pipeline

New antihistamine for pediatric patients in the U.S.

Dual thromboxane synthase/lipoxygenase inhibitors from Nikken Chemicals

Treatment for cystic fibrosis patients progresses on schedule

Approval of Pulmozyme recommended for new indication

Respiratory R&D at Yamanouchi

Respiratory drugs in Fujisawa's product pipeline

Warner-Lambert claims endothelin antagonists

Endothelin antagonists from Banyu

Wakunaga discloses angiotensin II antagonists

Neurex and Beaufour Ipsen reach licensing agreement for Corlopam

MTP inhibitors from Bristol-Myers Squibb

New antioxidant for atherosclerosis

Lynx licenses antisense compound for restenosis to Schwarz

Clinical results with adenosine agonist

New approval for carvedilol in congestive heart failure

BTG licenses drug for cardiac arrest

Significant progress in cardiovascular R&D at Yamanouchi

Fibrinogen antagonist research continues at Merck & Co.

Antiplatelet fibrinogen antagonists from Yamanouchi

Integrin receptor antagonists described by SKB

Fujisawa's antiplatelet agent in clinical trials

Bristol-Myers Squibb to develop Toray antiplatelet agent in the U.S. and Canada

Further launches scheduled for tamsulosin

New BPH therapy cleared by the FDA

Three renal-urologic drugs reported in the Fujisawa product pipeline

Renal-urologic drugs in development at Yamanouchi

Zenyaku Kogyo discloses anti-Helicobacter pylori agents

European approvals for Zantac

Medeva acquires rights to nicotine for ulcerative colitis

New hepatoprotectants from Nisshin Flour Milling

Promising results from U.S. trial on Zadaxin for hepatitis C

Axcan acquires enzyme preparation for pancreatic insufficiency

Gastrointestinal drugs in the pipeline at Fujisawa

Yamanouchi reports on GI drugs in development

Progress in development of NPS's R-568

Nissan Chem. claims hypoglycemic agents for diabetes

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

UCSF scientists discover protein involved in insulin resistance

New approval for Lilly's Humalog

Antidiabetic agents from Yamanouchi's clinical pipeline

Aldose reductase inhibitor in phase III at Fujisawa

Muse approvable for treatment of impotence

Improved formulation of Testoderm available in U.S.

Yamanouchi awaits marketing approval for new contraceptive

Atosiban efficacy in treating preterm labor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...